MAZ

Across TCGA pan-cancer cohorts, MAZ mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAZ data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAZ mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAZ expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where MAZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.946	0.734	.005	17	view →
LUAD	OS	Median	All	1.000	0.653	.002	16	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	14	view →
UCEC	DFS	Median	II,III,IV	0.531	0.866	.026	10	view →
PDAC	OS	Quartile	II,III,IV	0.384	0.747	.003	8	view →
HNSC	OS	Quartile	All	0.413	1.000	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAZ–LSCC (OS)

Open the LSCC breakdown →